8 August 2025 - trading update
The AIM-listed developer, manufacturer and provider for rapid tests and med-tech has provided a trading update for the year to 30 June 2025. This has confirmed that revenues for the year are in line with expectations at £8.6m (2024: £6.1m) with further significant revenue growth expected in the new financial year. The group has won a number of new contracts during the financial year with one worth $2m for tests for sexually transmitted diseases, whilst it has also won contracts for diagnostic testing with a European biotech company and the development . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
